**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 7491**

**Columns:** **TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (9): Hepatitis B virus

**Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis**

Tarocchi M *et al.* HBV and HCC

Mirko Tarocchi, Simone Polvani, Giada Marroncini, Andrea Galli

**Mirko Tarocchi, Simone Polvani, Andrea Galli,** Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50139 Florence, Italy

**Giada Marroncini, Andrea Galli,** FiorGen Foundation, 50139 Florence, Italy

**Author contributions:** Tarocchi M made the literature review and wrote the paper; Polvani S critically revised the manuscript; Marroncini G critically revised the manuscript; Galli supervised the manuscript.

**Supported by** Cassa di Risparmio di Firenze (CRF) and FiorGen Foundation

**Correspondence to: Andrea Galli, MD, PhD, Professor,** Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini n°6, 50139 Firenze, Italy. andrea.galli@unifi.it

**Telephone**: +39-55- 4271294 **Fax**: +39-55-4222409

**Received:** January 21, 2014 **Revised:** March 5, 2014

**Accepted:** April 15, 2014

**Published online:**

**Abstract**

Hepatitis B virus (HBV) infection is a global public health problem with approximately 2 billion people that have been exposed to the virus. HBV is a member of a family of small, enveloped DNA viruses called hepadnaviruses, and has a preferential tropism for hepatocytes of mammals and birds. Epidemiological studies have proved a strong correlation between chronic hepatitis B virus infection and the development of hepatocellular carcinoma (HCC). HCC is the fifth most common malignancy with about 700000 new cases each year, and more than 50% of them arise in HBV carriers. A large number of studies describe the way in which HBV can contribute to HCC development. Multiple mechanisms have been proposed, including the accumulation of genetic damage due to immune-mediated hepatic inflammation and the induction of oxidative stress. There is evidence of the direct effects of the viral proteins HBx and HBs on the cell biology. Integration of HBV DNA into the human genome is considered an early event in the carcinogenic process and can induce, through insertional mutagenesis, the alteration of gene expression and chromosomal instability. HBV has also epigenetic effects through the modification of the genomic methylation status. Furthermore, the virus plays an important role in the regulation of microRNA (miRNA) expression. This review will summarize the many mechanisms involved in HBV-related liver carcinogenesis.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words**: Hepatocellular carcinoma; Hepatocarcinogenesis; Hepatitis B Virus; Chronic hepatitis B infection; Cell biology

**Core tip:** Hepatitis B virus (HBV) infection is a global health problem. There is evidence that HBV have a causal role in the development of hepatocellular cancer, but the mechanism leading to the transformation of normal hepatocytes into cancer cells is still intricate. This review will summarize the many mechanisms involved in HBV-related liver carcinogenesis.

**HEPATOCELLULAR CARCINOMA**

Hepatocellular carcinoma is a highly prevalent and lethal neoplasia. It is fifth most common cancer in men and the ninth in women with respectively about 500000 and 200000 new cases per year; looking in detail the major number comes from Asia (76%), followed by Europe (8.1%), Africa (7.5%), North America (4.2%), Latin America and Caribbean (3.8%) and Oceania (0.4%)[1]. The global distribution of these new cases is uneven and reflects the differences in the exposition of the local populations to the different etiological factors: in Eastern Asia and Sub-Saharan Africa the dominant risk factor is chronic HBV infection, while in North America, Europe and Japan HCV infection together with excessive alcohol intake are the main risk factor. Furthermore in developed countries the increasing incidence of obesity and consequently of non-alcoholic steatohepatitis is becoming an important risk factor for cirrhosis and HCC as well[2-3]. Other risk factors include type 2 diabetes, hemochromatosis, Wilson`s disease, alpha-1 antitrypsin deficiency, glycogen-storage diseases, autoimmune hepatitis, tyrosinemia and some porphyries[4-6]. Independently from the etiologic factor underlining the presence of chronic liver disease, cirrhosis should be consider major risk factor, in fact 70%-90% of HCC develop from these group of patients.

Even if in the last decades the management of HCC is improved due to the increase diagnostic capacity, the development of evidence-based staging system and the availability of new effective treatments the prognosis is still very poor (overall ratio of mortality to incidence of 0.95)[1] suggesting that a deeper comprehension of the molecular pathway involved in the hepatocarcinogenic process is necessary to improve the outcome of HCC patients.

**HBV BACKGROUND**

Hepatitis B virus (HBV) infection is a major global public health problem with approximately 2 billion people that present evidence of contact with the virus. Considering that more than 350 million individuals in the global population are chronic HBV carriers, this virus stands as one of the most common human pathogens[7]. The risk of developing chronic hepatitis B (CHB) infection after an exposure seems to depend on the age at which the virus is first contracted[8]. Infection within the first year of life has a 90% chance in developing a CHB; infections in childhood represent a risk of 20%-30%; less than 1% of the exposure in adults go on to develop CHB [8]. Chronic infection may progress to cirrhosis and ultimately hepatocellular carcinoma (HCC). CHB infection remains the major etiological factor of HCC worldwide with more than one half of HCC patients being HBV infected[9]. Several observations indicate an etiologic association between CHB and the development of HCC including a high prevalence of HBV surface antigen (HBsAg) among HCC patients. CHB increases up to a 20-fold the risk of developing HCC also in the absence of cirrhosis. The REVEAL-HBV study found that serum HBV DNA levels and HCC risk correlate in a linear relationship[10]. Furthermore the presence of HBV-DNA integration within the hepatic cells increases about 100 times the relative risk for HCC among HBsAg carriers compared with negative individuals[11].

Specific viral and host factors can contribute to an increased risk of HCC among patients with CHB: increasing age, male gender, and longer duration of infection, all increase the risk of HCC and the presence of cirrhosis is the single most-important risk factor for HCC[12].

Host genetic background is known to have an influence in the story of the disease; in fact belonging to a specific ethnical group increases the susceptibility of HBV carrier to develop HCC. Among all Africans have the worst outcome, followed by Asians[13]. In these two geographic areas more than 70% of HCC develop in patients with HBV infection[14]. In Asia annual incidence among HBV carriers is more than 0.2% with a risk of HCC development before the cirrhotic stage[15]. In Africa of great importance is the potential aflatoxin exposure that increases highly the risk, obliging to start HCC surveillance in youth. The synergic effect of HBV infection and aflatoxin exposure increases the risk to develop HCC by 60 time compared to healthy individuals [16].

Several meta-analysis tried to associate genetic polymorphisms with an increased risk of HCC in CHB carriers; contradictory evidences are present in literature. While more studies are needed to unveil the mechanisms connecting some of these genetic changes to HCC, current results suggest a positive correlation of TNFα and GSTT1 polymorphisms with HCC[17]. On the viral side, for a long time the attention has been focused on high viral load as predictive for HCC development, but other viral risk factors have been found including the viral genotype. Until now 11 HBV genotypes (A–J) have been identified, based on differences in their genome sequence[18]. HBV genotypes have distinct geographical and ethnic distributions: genotype A is pandemic but most prevalent in northern Europe, North America and central Africa; genotypes B and C are found in eastern Asia, Korea, China, Japan, Polynesia and Vietnam; genotype D is also pandemic but is predominant in the Mediterranean area, the Middle East and India; genotype E is typical for Africa; genotype F is found in Native Americans and in Polynesia; genotype G is present in western Europe and North America and genotype H is found predominantly in Central America. The epidemiological evidences indicate that the genotype C has a higher risk of causing HCC than B, and D has a higher than A[19]. Furthermore the presence of enhancer II/basal core promoter mutations (A1762T/G1764A), and mutants with preS deletions are associated as well with increased risk of HCC[20-21]. External cofactors that can also promote HCC development in CHB carriers are concomintant infection with human immunodeficiency virus (HIV), hepatitis C or D virus, cigarette smoking, environmental pollution, chronic alcohol consumption, aflatoxin exposition, and metabolic syndrome[12,17,22]. HCC is the third leading cause of cancer-related death worldwide[23]. Recent epidemiological data have demonstrated that liver cancer incidence is continuously rising and will continue to do so for more than a decade, not only in Asia and Africa but also in North America and Europe[9]. Despite the availability of an efficacious and safe hepatitis B vaccine[24], about 600000 people die worldwide every year due to either the acute or chronic effects of the virus, with a high proportion dying of HCC. In this context, advances in our understanding of the molecular basis of HCC are urgently needed to develop early tumour markers and novel targeted agents with improved therapeutic efficiency[25]. Here we review the molecular mechanisms linking CHB to malignant transformation of liver cells.

**HEPATITIS B VIRUS**

HBV is a member of a family of small enveloped DNA viruses called hepadnaviruses, which infect a restricted number of mammals and birds. These viruses share a narrow host range and preferential tropism for hepatocytes. The genome of hepadnaviruses is a circular, partially double-stranded DNA genome that replicates via an RNA intermediate[26]. The HBV genome consists of two asymmetric DNA strands, which forms a partially double-stranded relaxed circular DNA structure that is around 3.2 kb in length. The HBV genome is organized into 4 overlapping open-reading frames (ORFs) that give rise to 5 messenger RNAs (mRNA). The largest one is a 3.5-kb mRNA strand that is composed of two subspecies: a 3.5-kb precore/core mRNA that is translated into the e antigen (HBeAg), and a second 3.5-kb strand termed the pregenomic mRNA that is translated into the core and polymerase proteins. The remaining mRNAs include the 2.4 kb large and 2.1 kb small surface mRNAs, which encode the three viral surface proteins. The 0.7 kb small mRNA gives rise to the hepatitis B X (HBx) protein that is essential for virus replication and appears to play an important role in HBV-induced HCC. The HBV genome encodes also a 2.2 kb singly spliced pre-genomic RNA producing the newly discovered hepatitis B spliced protein (HBSP) involved in proliferation and viability of HBV-infected cells[27-28].

The HBV enters the hepatocytes and releases, by disintegration of the nucleocapsid, the relaxed circular DNA (rcDNA) that can be transported to the nucleus, where it is converted into covalently closed circular DNA (cccDNA). It is present in the nucleus of infected hepatocytes bound to both histone and nonhistone proteins, in a stable freestanding episomal conformation. cccDNA serves as the template for transcription of all viral mRNAs and is unaffected by all current nucleotide analog antivirals because they inhibit DNA replication, which occurs after cccDNA formation. In fact cccDNA persists during therapy even after the clearance of HBsAg, and this is the reason why disease recurrence is possible even after successful treatment[29-30].

**MECHANISMS OF HBV-RELATED HCC INDUCTION**

HBV can promote HCC in many ways. There is a large amount of data describing the multiple pathways involved in this process, including the accumulation of genetic damage due to immune-mediated hepatic inflammation, the induction of oxidative stress, a virus-specific mechanisms involving the viral proteins HBx and HBs, the insertional mutagenesis with integration of HBV DNA into the host genome that alters the expression of endogenous genes or induces chromosomal instability, epigenetic modification through the modification of the genomic methylation status and also the regulation of microRNA (miRNA) expression.

### *Immune and inflammatory factors*

In many different tissues chronic inflammation is known to play a vital role in cancer development. In the liver, repeated cycles of inflammation induced apoptosis and hepatocyte regeneration, increasing the risk of hepatocarcinogenesis. T cell dysfunction, cytokine production, and inflammation-mediated alteration of specific signaling pathways play important role in the development of HCC. During inflammation, the activation and interaction between STAT3 and NF-κB play vital roles in controlling the communication between cancer cells and inflammatory cells. NF-κB and STAT3 are two major factors that keep in check the ability of pre-neoplastic and malignant cells to resist apoptosis-based tumor-surveillance and regulate tumor angiogenesis and invasiveness. HBV infection and inflammation induced NF-κB activation, that in turn promoted immune escapes, facilitating the development of HCC. STAT3 activation induced by IL-6, IL-6 cytokine family, and IL-22, also promoting the development of HCC[31,32].

In the immune system, CD4+Th1 and CD8+ T cells play an important role in the growth inhibition and the death of cancer cells. This ability seems to be related to their capability to secrete INF-γ, but other cytokines may be involved; in several experimental studies have been proved that the depletion of these population of T cells impaired the immune response against the cancers and the rejection of the implanted tumor cells suggesting theirs involvement in the immune response against cancer[33]. Differently the regulatory T cells (Treg) are a subpopulation of T cells (CD4+ CD25+ Foxp3+) which maintain tolerance to self-antigens, and abrogate autoimmune disease by suppressing immune responses of other cells. Treg cells have been reported to play a key role in the immune impairment involved in HBV-related HCC. Elevated TGF-β activity, associated with the persistent presence of HBV in the liver tissue, suppresses the expression of miRNA-34a, leading to enhanced production of chemokine CCL22, which recruits Treg cells[34]. HBV infection was found to increase the immunomodulatory activity of Treg by up-regulating the expression of forehead box P3 transcriptional regulator (FoxP3), cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and glucocorticoid-induced tumor necrosis factor (TNF) receptor family gene (GITR). The expansion of Treg cells and the enhancement of their suppressor function prevent the anti-tumor immune response against HCC tumor antigens and inhibit tumor immune surveillance against HCC[35]. Finally, Li et al. were able to investigate Treg cells in the circulatory blood and tumor tissues of patients with HBV-related HCC and their data indicate that an increased amount of Treg cells either in peripheral blood or in the tumor tissue correlates to poor prognosis [36].

***HBV and oxidative stress***

In literature, there are many indications that HBV can induce a pro-oxidative status. In fact, increased level of oxidative stress, sulfhydryl and lipid peroxidation were found in CHB patients[37]. Additionally, typical products of reactive oxygen species (ROS) are enhanced in carriers with high HBV DNA titers[38].

Oxidative stress is a disturbance in the cellular equilibrium that can result from a lack of antioxidant deference capacity or by an increased production of ROS. The excess of ROS can damage lipids, proteins or DNA, and consequently alter different cellular pathways and influence gene expression, cell adhesion, cell metabolism, cell cycle and cell death. ROS-induced oxidative DNA damage can increase chromosomal aberrations associated with cell transformation[39]. ROS may also activate cellular signaling pathways, such as those mediated by mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB), phosphatidylinositol 3-kinase (PI3K), p53, FOXO, β-catenin/Wnt, COUTFII and others associated with angiogenesis[40-42].

Because of the role of these pathways in mutagenesis, tumor promotion, and progression, ROS are considered potential carcinogens[43].

*In vivo* and *in vitro* experiments have shown that HBV infection is able to induce oxidative stress by reproducing the same increase found in CHB patients. Furthermore, to demonstrate that oxidative stress plays a critical role in hepatic injury, several studies showed that the total peroxide levels, a parameter of oxidative stress, as well as alanine aminotransferase (ALT) levels are significantly higher in patients with chronic hepatitis compared to asymptomatic carriers[44].

Interestingly, transgenic mice that produce and accumulate HBsAg inside the hepatocytes have increased levels of inflammation and oxidative stress before the development of dysplastic foci and HCC[45-46]. Moreover, transgenic mice that express HBx protein[47] have high levels of ROS, suggesting that the viral induction of oxidative stress occurs through many mechanisms.

Mitochondria are a major source of ROS inside the cells, which can be produced through electron leakage from the mitochondrial respiratory chain[48]. HBx targets mitochondria binding to the voltage-dependent anion-selective channel protein 3 (VDAC3), and alters the mitochondrial membrane potential and increases endogenous ROS levels[49-51]. HBx also induces oxidative stress through cytosolic calcium signaling, resulting in Ca++ accumulation into mitochondria, consequent increased levels of ROS and activation of cellular kinases (PYK2 and SRC kinases), leading to the activation of transcription factors NF-κB and STAT3 which promote HBV replication and early steps of HCC[52-54]. The increased level of Ca++ in presence of ROS can trigger endoplasmic reticulum (ER) stress and the unfolded protein response (UPR). In fact, if the ER stress remains constantly elevated, UPR signaling cannot be maintained and the cell activates the autophagic process to restore ER integrity, which is important for viral replication[55]. HBx alone in the context of whole viral genome transfections caused the mitochondrial translocation of mitogen-activated protein kinase Raf-1. This event induced by oxidative stress involves the Src- and the PAK-mediated phosphorylation of Raf-1, leading to its activation[56]. HBx also influences the lipid peroxidation via downregulation of SeP expression, resulting in increased expression of TNF-α as shown in an *in vitro* study in the human hepatoblastoma cell line HepG2[57].

Other HCC cell lines (human HuH7 and murine ML1-4a), stably transfected with the pre-S mutants (truncated forms of preS/S polypeptide), exhibited enhanced levels of ROS through endoplasmic reticulum (ER) stress pathways. The oxidative DNA damage has also been confirmed in the livers of transgenic mice carrying the pre-S mutant[58].

***HBV DNA Integration***

Another proposed mechanism of induction of HCC by HBV is through its integration in the host genome. HBV DNA integration into human host chromosomes occurs in the infected liver since early stages of natural acute infections. Multiple integrations have been detected in chronic hepatitis tissues, and integrated HBV sequences have been seen in 80%-90% of HBV-related HCCs[59]. HBV insertions have been associated with major genetic alterations within the cell genome, including generalized genomic instability, gene and chromosomal deletions and translocations, amplification of cellular DNA, and generation of fusion transcripts [60-61]. These alterations in the host genome may alter the expression of miRNAs, oncogenes, and tumor-suppressor genes, events that could lead to the development of HCC.

Early studies suggested that viral integration into the host gene occurred randomly, but in the last decades with the introduction of whole genome sequencing, several groups were able to identify some preferred site for HBV integration, typically close to or inside of certain target genes, such as TERT (telomerase reverse transcriptase ), FN1 (Fibronectin 1), SMAD5 (SMAD family member 5), MLL4 (Myeloid/lymphoid or mixed-lineage leukemia 4), ARHGEF12 (Rho guanine nucleotide exchange factor GEF 12), CYP2C8 (Cytochrome P450, family 2, subfamily C, polypeptide 8), PHACTR4 (Phosphatase and actin regulator 4), PLXNA4 (Plexin A4), RBFOX1 (RNA binding protein, fox-1 homolog), ADH1B (Alcohol dehydrogenase 1B), CPS1 (Carbamoyl-phosphate synthetase 1), ESRRG (Estrogen-related receptor gamma), LRFN2 (Leucine rich repeat and fibronectin type III domain containing 2), MYOM1 (Myomesin 1), RAI1 (Retinoic acid induced 1), CTDSPL2 (CTD small phosphatase like 2), LRP1B (Low density lipoprotein-related protein 1B), SENP5 ( SUMO1/sentrin specific peptidase 5), ROCK1 (Rho-associated, coiled-coil containing protein kinase 1), PDGF receptor and CCNE1 (cyclin E1) [59, 62-64]. The identification of these and other recurrent sites of viral integration inside or in the proximity of genes controlling cellular proliferation, survival, differentiation and immortalization, suggests that this process may indeed be involved directly in hepatocarcinogenesis.

However, evidence for fusion proteins came from a direct promoter insertion mechanism that was first provided in HBV-related HCC where insertion targeted either the retinoic acid receptor-β (RAR-β) gene or the human cyclin A gene, resulting in tumour-specific chimeric proteins endowed with novel, pro-carcinogenic functions.

Finally, although integrated viral sequences are defective for replication, they might also contribute to tumorigenesis through the production of truncated and mutated HBx or preS2/S proteins. These proteins may act on HCC development by disrupting the control of cellular gene expression or by activating oncogenic signaling pathways[65-66].

***DNA methylation***

DNA methylation is one of the most intensely studied epigenetic modifications in mammals. Aberrant DNA methylation patterns - hypermethylation and hypomethylation compared to normal tissue - have been associated with a large number of human cancers. Hypermethylation typically occurs at CpG islands in the promoter region and is associated with the inactivation of certain tumor-suppressor genes. The enzymes responsible for the maintenance of methylation patterns are the DNA methyltransferases (DNMT) and a large body of evidence shows that HBx upregulates DNMT1, DNMT3A1 and DNMT3A2[67]. Conversely, global hypomethylation has also been reported to induce genomic instability and contribute to cell transformation and progression of cancer.

In HCC, alteration of DNA methylation occurs in the early stage of cancer development, and in these patients the increased risk of cancer development was due both to genomic hypomethylation with related increased chromosome instability and localized hypermethylation with decreased tumor suppressor gene expression[67].

Lately, DNA hypermethylation in the promoter region of specific oncosoppressor genes was found in HBV-related HCC[68-70]: RASSF1A (Ras association domain family member 1), p16INK4A and P21WAF1/CIP1 are involved in cell cycle maintenance and their altered expression is an early event in the development of HCC; CDH1 (E-cadherin) is involved in cell adhension and metastatization; GSTP1 downregulation exposes cells to oxidation damage and electrophilic carcinogens; ASPP1 and ASPP2 have an important role in apoptosis. Alterations were found also in the promoter region of hTERT, maintaining its expression and increasing proliferative capacity of the cell, and in the promoter region of COX-2 leading to a more proinflammatory state.

***HBx protein***

The viral protein HBx is a 154 amino acid long protein acting as a pleiotropic transactivator; it does not bind directly to DNA but rather acts on cellular promoters by protein-protein interactions and modulating cytoplasmic signaling pathways.

Interestingly HBx is expressed at low levels during acute and chronic hepatitis and can induce a humoral and cellular immune response[71-72]. Thanks to viral DNA integration into the host genome, the HBx gene is maintained and transcribed in human HCC tumor cells even if complete HBV replication is absent[73-74].

In the cytoplasm, it activates mitogenic signaling cascades while in the nucleus it modulates gene expression via interaction with numerous transcription factors. The large body of evidences suggests its central function in a large number of signaling pathways involved in oncogenesis, proliferation, apoptosis, inflammation and immune response. Furthermore, HBx may act as a paracrine factor and activates stellate cells[75-76].

HBx play a role in cromosomal instability by targeting centrosome dynamics and mitotic spindle formation through its binding with different cellular partners implicated in centrosome formation. HBx has been suggested to induce multipolar spindle formation, chromosome segregation defects, and appearance of multinucleate cells by inducing aberrant centrosome duplication; these biological actions might be due to sequestration of the nuclear transport receptor Crm1 in the cytoplasm[77], and/or HBx binding to the hepatitis HBx interacting protein (HBXIP), a regulator of centrosome duplication[78] or to the UV-damaged DNA binding protein 1 (DDB1)[79] and induction of lagging chromosomes by binding to BubR1[80].

HBx may increase the expression of matrix metalloproteinase and facilitated cellular migration [81-83].

HBx transactivates a number of cellular promoters and enhancers containing binding site for NF-kB, activator protein 1 (AP-1), AP-2, CCAAT-enhancer-binding protein (c-EBP), RNA polymerase and nuclear factor of activated T-cells (NF-AT), cellular promoter of genes associated with cell proliferation as IL-8, TNF, transforming growth factor (TGF) beta and epidermal growth factor receptor (EGRF) and cytosolic signal transduction pathways as Ras/Raf mitogen-activated protein kinase, Src kinases, cJun Nterminal kinase, Jak1/STAT and protein kinase (PK)[84-85], which have overlapping effects on cell proliferation and viability.

HBx interacts with the acetyltransferases CBP/p300, and this interaction induces the activation of CREB-dependent transcription. The activation of CREB/ATF trans-activation function by HBx appears redundant since HBx has been shown to increase CREB/ATF DNA-binding affinity as well as to enhance the recruitment of CBP/p300 to CREB/ATF bound to cellular DNA [86-87]. The modulation of CREB/ATF plays an essential role in liver metabolism and proliferation, and CREB has been implicated in hepatocarcinogenesis[88].

Important targets of HBx are p53 and p53 family[89]. In fact, the viral protein directly binds to p53 and impairs its function. HBx, through the interaction with p53, can alter p53-mediated apoptosis, transactivation properties of p53[90], cell cycle regulation [91], DNA repair genes[92-93], and tumor suppressor genes[71].

In the mitochondria HBx interacts with the heat shock protein 60 and 70 [94] and the voltage dependent anion channel (VDAC) isoform VDAC3[50].

HBx seems to regulate the angiogenic process in HCC[95-98]. Indeed, HBx expression induces transcriptional up-regulation of the vascular endothelial growth factor (VEGF) and the proangiogenic growth factor angiopoietin 2 (ANG2). It also plays an important role in the hypoxia inducible factor HIF-1 cellular level. In fact HBx binds to and stabilizes HIF1α and at the same time stimulates HIF1α transcription, thus promoting angiogenesis.

HBx can activate Wnt/beta-catenin signaling in two different ways: by up-regulating cytoplasmic beta-catenin[99] or alternatively by hypermethylating E-cadherin promoter and consequently repressing its transcription[100].

***HBV preS/S proteins***

The preS/S ORF encodes three different, structurally related envelope proteins refered to as the large (L), middle (M), and small (S) proteins that are synthesized from alternative initiation codons. These three proteins share the same carboxy-terminus part but have different amino-terminal extensions. In particular, the S protein corresponding to the HBV surface antigen (HBsAg) consists of only 226 amino acids (aa), the M protein contains an extra N-terminal extension of 55 aa, and the L protein has a further N-terminal sequence of 108-119 aa compared with the M protein. Until now, few mechanisms of action of preS/S encoded proteins have been known to be involved in the hepatocarcinogenic process. During HBV replicative cycle, HBsAg can accumulate into the ER, induce ER stress and consequently increase the cellular level of oxidative stress. This process happens also in presence of pre-S2 mutants in which the viral proteins amass in the ER. The induced ER stress upregulates the cytoplasmic Cyclin A, increasing infected cell proliferation; at the same time, Cyclin A upregulation can promote, through centrosome over-duplication, chromosome instability which is a well-known mechanism in HBV-related hepatocarcinogenesis[101].

Additionally, HBsAg seems to have an effect on the mitochondrial function: on one hand it binds to enoyl coenzyme A hydratase short chain 1 (ECHS1) and can induce cell apoptosis by decreasing the mitochondrial membrane potential (MMP)[102], while on the other hand HBsAg could inhibit JTB (jumping translocation breakpoint), leading to increased cell motility and decreased apoptosis[103]. Interestingly, pre-S2 mutant protein in type II ground glass hepatocytes (GGHs) could directly interact with the c-Jun activation domain-binding protein 1 (JAB1), inducing an hyperphosphorylation of the tumor-suppressor retinoblastoma (RB) and its inactivation[104].

Futhermore, pre-S2 protein can act as a transactivator and, interacting with the hTERT promoter[105], increase telomerase activity, a key step in the development of HCC and other cancers. Interestingly, HBV is also able to upregulate of telomerase activity by HBV DNA integration in proximity of the promoter[106] or by HBx capacity to increase the SP1 binding to hTERT promoter and induce its transcription[107]. Despite hTERT activation, telomere in HCC cells remain shorter than in normal somatic cells, predisposing to occasional telomere and chromosomal instability, and polyploidy[108]

***miRNAs***

MiRNAs are small non-coding RNA molecules (19-25 nucleotides in length) that regulategene expression at transcriptional and post-transcriptional levels, usually resulting in gene silencing via translational repression or target degradation of gene mRNA. Since their discovery in the early 1990s, over 1000 miRNAs have been characterized in human cells. In the last decade, many groups have investigated the role of this biological entity in patho-physiological processes; several publications have unveiled the function of miRNAs in the development, progression and metastatization of HCC. Specifically, a growing number of studies were able to identify specific miRNAs modulated in CHB patients; some of them are regulated by HBV infection and have a role in hepatocarcinogenic process.

miR-143, miR-34, and miR-19 have been found to be upregulated in HBV-related HCC and to promote a more aggressive cancer phenotype, while Let-7a downregulation by HBx increased cell proliferation[109]. HBx also downregulates miR-152 with the consequent upregulation of DNMT1, which methylates the promoters of many tumor suppressor genes. Interestingly, other publications reported additional miRNAs that are involved in HBV-related HCC [110]: miR-221, which is downregulated in acute HBV infection, normally expressed in chronic HBV infection and upregulated in HCC; miR-101, which is constantly downregulated in HBV infection and in HCC tissues, has been associated with HCC development; miR-18a/miR-18b and miR-106a may be key effectors for the progression of HCC. Very recent data suggest other possible miRNAs involved in HCC development in CHB patients: miR-224 that is inversely correlated to autophagy in HBV-related HCC specimens[111], miR-122 that is regulated by HBx through PPARg[112], miR-15a and miR-16-1 directly downregulated by HBx[113], miR-132 regulated by the hypermethylation status induced by HBx[114], or miR-148 that is also downregulated by HBx through the suppression of p53-mediated activation[115]. Recently, Xu *et al*[116] reviewed the HBV-HCC correlation and reported miR-602, miR-143, miR-29a, miR-148a, miR-373, miR-101, miR-152, miR-16, and miR-661 as miRNAs possibly implicated in the carcinogenic process. In the future, more extensive analysis will be able to create a precise profile of HBV modulation of miRNAs and their function in the different phases of the hepatocarcinogenetic process.

**FUTURE THERAPEUTIC STRATEGIES**

Up today HCC remain a devastating cancer, so the safest strategy remain the prevention, through the control of the risk factors. Prevention of HBV infection among them can be accomplished by large scale vaccination or in patients with preexistent CHB a continued suppression of HBV replication with antiviral ( *e.g.,* entecavir and adefovir dipivoxil) can prevent complications of HBV-related liver disease and decrease the risk of HBV-related HCC development[117]. In fact the REVEAL-HBV study suggests that the degree of HBV viremia predicts HCC risk independently of cirrhosis, HBeAg+ or ALT levels, introducing the concept that virologic suppression through antiviral therapy may have a major impact on the prevention of liver cancer. After the rise of HCC then the treatment selection follows the Barcelona Clinic Liver Cancer (BCLC) staging system that assigns the prognosis and proposes the therapeutic strategies for each stage. In the proposed strategies only one systemic chemotherapeutic molecule (Sorafenib) is approved as first line of treatment. Since the emergence of Sorafenib as the new standard for the systemic treatment of HCC, the idea of targeting specific molecular pathways implicated in the pathogenesis and progression of HCC, has promoted a revolutionary change in the treatment of this disease. Genetic modifications and alteration of critical molecular signaling pathways have been identified as contributing to the tumor development and progression. Among the numerous signaling pathways implicated in the development and growth of HCC are worth to be noted Ras/Raf/MAPK, Wnt-b-catenin, EGFR, insulin-like growth factor receptor, VEGFR, NF-KB, AKT-mTOR, Notch and Hedgehog. Thanks to the acquired knowledge on altered pathways in HCC several promising novel anticancer agents are currently under evaluation (56 drugs)[118] including tyrosine kinase inhibitors, monoclonal antibodies and oligonucleotide antisense. Furthermore monotherapy can be very effective in vitro but targeting one pathway may result in the activation of other pathways in HCC cells suggesting that the most attractive strategy for the future should be the combination of different targeted agents to improve the efficacy of these molecules[119-120]. Research will permit a more comprehensive understanding of hepatocarcinogenic process and to identify new molecular targets for therapeutic intervention.

**CONCLUSION**

Among the different etiologic agents, HBV is the major risk factor for developing HCC. In the future, the global neonatal vaccination program will greatly reduce the burden of HBV and ultimately of HCC, but more than 700000 new HCC cases are still identified each year. In the last decades, progresses have been made in understanding the multifactorial process through which HBV infection can promote hepatocarcinogenesis. On one hand, HBV infection is able to induce a chronic inflammatory status in the patient, to increase the oxidative stress and to modulate the host immune response against infected hepatocytes. On the other hand, HBV DNA integration may lead to chromosomal instability and alteration of gene expression. Furthermore, HBV products directly disrupt normal cellular signal pathways, contributing to induce HCC. Other factors like genomic methylation and miRNA expression have been identified to play a role in HBV-related development of HCC.

A deeper knowledge of the mechanisms that mediate the HBV carcinogenic process is essential for developing novel strategies to prevent and treat liver cancer in chronic HBV carriers.

**REFERENCES**

1 **Ferlay J SI,** Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: URL: http: //globocan.iarc.fr, accessed on 27/02/2014. 2013

2 **Mittal S**, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. *J Clin Gastroenterol* 2013; **47** Suppl: S2-S6 [PMID: 23632345 DOI: 10.1097/MCG.0b013e3182872f29]

3 **Fares N**, Péron JM. [Epidemiology, natural history, and risk factors of hepatocellular carcinoma]. *Rev Prat* 2013; **63**: 216-27, 216-27, [PMID: 23513788]

4 **Franco LM**, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, Boney A, Sullivan J, Frush DP, Chen YT, Kishnani PS. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. *J Inherit Metab Dis* 2005; **28**: 153-162 [PMID: 15877204 DOI: 10.1007/s10545-005-7500-2]

5 **Dorfman JD**, Schulick R, Choti MA, Geschwind JF, Kamel I, Torbenson M, Thuluvath PJ. Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. *World J Gastroenterol* 2007; **13**: 781-784 [PMID: 17278203]

6 **Montalto G**, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. *Ann N Y Acad Sci* 2002; **963**: 13-20 [PMID: 12095924]

7 **Ganem D**, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. *N Engl J Med* 2004; **350**: 1118-1129 [PMID: 15014185 DOI: 10.1056/NEJMra031087]

8 **Fattovich G**, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. *J Hepatol* 2008; **48**: 335-352 [PMID: 18096267]

9 **Parkin DM**. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer* 2006; **118**: 3030-3044 [PMID: 16404738 DOI: 10.1002/ijc.21731]

10 **Chen CJ**, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; **295**: 65-73 [PMID: 16391218]

11 **Kao JH**, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. *Adv Cancer Res* 2010; **108**: 21-72 [PMID: 21034965]

12 **Yang JD**, Roberts LR. Hepatocellular carcinoma: A global view. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 448-458 [PMID: 20628345]

13 **Sherman M**, Bruix J, Porayko M, Tran T. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. *Hepatology* 2012; **56**: 793-796 [PMID: 22689409 DOI: 10.1002/hep.25869]

14 **Beasley RP**. Hepatitis B virus. The major etiology of hepatocellular carcinoma. *Cancer* 1988; **61**: 1942-1956 [PMID: 2834034]

15 **Yu MW**, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, Chen PJ, Hsiao TJ, Lee PH, Chen CJ. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. *J Natl Cancer Inst* 2000; **92**: 1159-1164 [PMID: 10904089]

16 **Kew MC**, Macerollo P. Effect of age on the etiologic role of the hepatitis B virus in hepatocellular carcinoma in blacks. *Gastroenterology* 1988; **94**: 439-442 [PMID: 2446950]

17 **El-Serag HB**. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology* 2012; **142**: 1264-1273.e1 [PMID: 22537432]

18 **Roman S**, Panduro A. HBV endemicity in Mexico is associated with HBV genotypes H and G. *World J Gastroenterol* 2013; **19**: 5446-5453 [PMID: 24023487 DOI: 10.3748/wjg.v19.i33.5446]

19 **Tan YJ**. Hepatitis B virus infection and the risk of hepatocellular carcinoma. *World J Gastroenterol* 2011; **17**: 4853-4857 [PMID: 22171125 DOI: 10.3748/wjg.v17.i44.4853]

20 **Yeung P**, Wong DK, Lai CL, Fung J, Seto WK, Yuen MF. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. *J Infect Dis* 2011; **203**: 646-654 [PMID: 21227916]

21 **Yuen MF**, Tanaka Y, Shinkai N, Poon RT, But DY, Fong DY, Fung J, Wong DK, Yuen JC, Mizokami M, Lai CL. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. *Gut* 2008; **57**: 98-102 [PMID: 17483190]

22 **Arciello M**, Gori M, Maggio R, Barbaro B, Tarocchi M, Galli A, Balsano C. Environmental pollution: a tangible risk for NAFLD pathogenesis. *Int J Mol Sci* 2013; **14**: 22052-22066 [PMID: 24213605]

23 **Gomaa AI**, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. *World J Gastroenterol* 2008; **14**: 4300-4308 [PMID: 18666317]

24 **Zanetti AR**, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. *Vaccine* 2008; **26**: 6266-6273 [PMID: 18848855 DOI: S0264-410X(08)01277-2]

25 **Avila MA**, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. *Oncogene* 2006; **25**: 3866-3884 [PMID: 16799628]

26 **Summers J**, Mason WS. Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. *Cell* 1982; **29**: 403-415 [PMID: 6180831]

27 **Chen JY**, Chen WN, Liu LL, Lin WS, Jiao BY, Wu YL, Lin JY, Lin X. Hepatitis B spliced protein (HBSP) generated by a spliced hepatitis B virus RNA participates in abnormality of fibrin formation and functions by binding to fibrinogen γ chain. *J Med Virol* 2010; **82**: 2019-2026 [PMID: 20981788 DOI: 10.1002/jmv.21918]

28 **Abu-Amara M**, Feld JJ. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma? *Semin Liver Dis* 2013; **33**: 157-166 [PMID: 23749672 DOI: 10.1055/s-0033-1345719]

29 **Beck J**, Nassal M. Hepatitis B virus replication. *World J Gastroenterol* 2007; **13**: 48-64 [PMID: 17206754]

30 **Levrero M**, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. *J Hepatol* 2009; **51**: 581-592 [PMID: 19616338]

31 **Fan Y**, Mao R, Yang J. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. *Protein Cell* 2013; **4**: 176-185 [PMID: 23483479 DOI: 10.1007/s13238-013-2084-3]

32 **He G**, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. *Cell Res* 2011; **21**: 159-168 [PMID: 21187858]

33 **Zamarron BF**, Chen W. Dual roles of immune cells and their factors in cancer development and progression. *Int J Biol Sci* 2011; **7**: 651-658 [PMID: 21647333]

34 **Yang P**, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, Deng Y, Zhao J, Jiang S, Yuan Y, Wang HY, Cheng SQ, Xie D, Wang XF. TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. *Cancer Cell* 2012; **22**: 291-303 [PMID: 22975373]

35 **Zhang HH**, Mei MH, Fei R, Liu F, Wang JH, Liao WJ, Qin LL, Wei L, Chen HS. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. *J Viral Hepat* 2010; **17** Suppl 1: 34-43 [PMID: 20586932]

36 **Li SP**, Peng QQ, Ding T, Xu J, Zhang CQ, Feng KT, Li JQ. [Clinical significance of regulatory T cells proportion in the peripheral blood and tumor tissue in primary hepatocellular carcinoma]. *Zhonghua Zhong Liu Za Zhi* 2008; **30**: 523-527 [PMID: 19062720]

37 **Duygu F**, Karsen H, Aksoy N, Taskin A. Relationship of oxidative stress in hepatitis B infection activity with HBV DNA and fibrosis. *Ann Lab Med* 2012; **32**: 113-118 [PMID: 22389877 DOI: 10.3343/alm.2012.32.2.113]

38 **Fujita N**, Sugimoto R, Ma N, Tanaka H, Iwasa M, Kobayashi Y, Kawanishi S, Watanabe S, Kaito M, Takei Y. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. *J Viral Hepat* 2008; **15**: 498-507 [PMID: 18331251]

39 **Choi J**, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. *Am J Physiol Gastrointest Liver Physiol* 2006; **290**: G847-G851 [PMID: 16603728]

40 **Tien Kuo M**, Savaraj N. Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. *Mol Carcinog* 2006; **45**: 701-709 [PMID: 16652372 DOI: 10.1002/mc.20240]

41 **Czaja MJ**. Cell signaling in oxidative stress-induced liver injury. *Semin Liver Dis* 2007; **27**: 378-389 [PMID: 17979074 DOI: 10.1055/s-2007-991514]

42 **Polvani S**, Tarocchi M, Galli A. PPARγ and Oxidative Stress: Con(β) Catenating NRF2 and FOXO. *PPAR Res* 2012; **2012**: 641087 [PMID: 22481913 DOI: 10.1155/2012/641087]

43 **Dröge W**. Oxidative stress and aging. *Adv Exp Med Biol* 2003; **543**: 191-200 [PMID: 14713123]

44 **Ha HL**, Shin HJ, Feitelson MA, Yu DY. Oxidative stress and antioxidants in hepatic pathogenesis. *World J Gastroenterol* 2010; **16**: 6035-6043 [PMID: 21182217]

45 **Dunsford HA**, Sell S, Chisari FV. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. *Cancer Res* 1990; **50**: 3400-3407 [PMID: 1692259]

46 **Galli A**, Ceni E, Mello T, Polvani S, Tarocchi M, Buccoliero F, Lisi F, Cioni L, Ottanelli B, Foresta V, Mastrobuoni G, Moneti G, Pieraccini G, Surrenti C, Milani S. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin. *Hepatology* 2010; **52**: 493-505 [PMID: 20683949 DOI: 10.1002/hep.23669]

47 **Ha HL**, Yu DY. HBx-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of PTEN/Akt pathway. *World J Gastroenterol* 2010; **16**: 4932-4937 [PMID: 20954279]

48 **Adam-Vizi V**, Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. *Trends Pharmacol Sci* 2006; **27**: 639-645 [PMID: 17056127]

49 **Lee YI**, Hwang JM, Im JH, Lee YI, Kim NS, Kim DG, Yu DY, Moon HB, Park SK. Human hepatitis B virus-X protein alters mitochondrial function and physiology in human liver cells. *J Biol Chem* 2004; **279**: 15460-15471 [PMID: 14724286 DOI: 10.1074/jbc.M309280200]

50 **Rahmani Z**, Huh KW, Lasher R, Siddiqui A. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. *J Virol* 2000; **74**: 2840-2846 [PMID: 10684300]

51 **Clippinger AJ**, Bouchard MJ. Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential. *J Virol* 2008; **82**: 6798-6811 [PMID: 18448529]

52 **Bouchard MJ**, Navas-Martin S. Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges. *Cancer Lett* 2011; **305**: 123-143 [PMID: 21168955]

53 **Bouchard MJ**, Schneider RJ. The enigmatic X gene of hepatitis B virus. *J Virol* 2004; **78**: 12725-12734 [PMID: 15542625]

54 **Waris G**, Huh KW, Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress. *Mol Cell Biol* 2001; **21**: 7721-7730 [PMID: 11604508 DOI: 10.1128/MCB.21.22.7721-7730.2001]

55 **Li J**, Liu Y, Wang Z, Liu K, Wang Y, Liu J, Ding H, Yuan Z. Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment. *J Virol* 2011; **85**: 6319-6333 [PMID: 21507968]

56 **Chen J**, Siddiqui A. Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress. *J Virol* 2007; **81**: 6757-6760 [PMID: 17428866]

57 **Yi YS**, Park SG, Byeon SM, Kwon YG, Jung G. Hepatitis B virus X protein induces TNF-alpha expression via down-regulation of selenoprotein P in human hepatoma cell line, HepG2. *Biochim Biophys Acta* 2003; **1638**: 249-256 [PMID: 12878326]

58 **Hsieh YH**, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, Chang WT, Huang W. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. *Carcinogenesis* 2004; **25**: 2023-2032 [PMID: 15180947 DOI: 10.1093/carcin/bgh207]

59 **Sung WK**, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C, Mulawadi FH, Wong KF, Liu AM, Poon RT, Fan ST, Chan KL, Gong Z, Hu Y, Lin Z, Wang G, Zhang Q, Barber TD, Chou WC, Aggarwal A, Hao K, Zhou W, Zhang C, Hardwick J, Buser C, Xu J, Kan Z, Dai H, Mao M, Reinhard C, Wang J, Luk JM. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. *Nat Genet* 2012; **44**: 765-769 [PMID: 22634754]

60 **Feitelson MA**, Lee J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. *Cancer Lett* 2007; **252**: 157-170 [PMID: 17188425]

61 **Bonilla Guerrero R**, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. *J Hepatol* 2005; **42**: 760-777 [PMID: 15826727]

62 **Li W**, Zeng X, Lee NP, Liu X, Chen S, Guo B, Yi S, Zhuang X, Chen F, Wang G, Poon RT, Fan ST, Mao M, Li Y, Li S, Wang J, Jianwang X, Jiang H, Zhang X. HIVID: an efficient method to detect HBV integration using low coverage sequencing. *Genomics* 2013; **102**: 338-344 [PMID: 23867110]

63 **Ding D**, Lou X, Hua D, Yu W, Li L, Wang J, Gao F, Zhao N, Ren G, Li L, Lin B. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. *PLoS Genet* 2012; **8**: e1003065 [PMID: 23236287 DOI: 10.1371/journal.pgen.1003065]

64 **Neuveut C**, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. *J Hepatol* 2010; **52**: 594-604 [PMID: 20185200]

65 **Garcia M**, de Thé H, Tiollais P, Samarut J, Dejean A. A hepatitis B virus pre-S-retinoic acid receptor beta chimera transforms erythrocytic progenitor cells in vitro. *Proc Natl Acad Sci U S A* 1993; **90**: 89-93 [PMID: 8093562]

66 **Wang J**, Zindy F, Chenivesse X, Lamas E, Henglein B, Bréchot C. Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. *Oncogene* 1992; **7**: 1653-1656 [PMID: 1321406]

67 **Park IY**, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH, Surzycki SJ, Lee YI. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. *Gastroenterology* 2007; **132**: 1476-1494 [PMID: 17408664]

68 **Rongrui L,** Na H, Zongfang L, Fanpu J, Shiwen J. Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis. *Curr Pharm Des* 2013; [PMID: 23888939]

69 **Zhao J**, Wu G, Bu F, Lu B, Liang A, Cao L, Tong X, Lu X, Wu M, Guo Y. Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region- containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. *Hepatology* 2010; **51**: 142-153 [PMID: 20034025 DOI: 10.1002/hep.23247]

70 **Calvisi DF**, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. *J Clin Invest* 2007; **117**: 2713-2722 [PMID: 17717605 DOI: 10.1172/JCI31457]

71 **Chun E**, Lee J, Cheong HS, Lee KY. Tumor eradication by hepatitis B virus X antigen-specific CD8+ T cells in xenografted nude mice. *J Immunol* 2003; **170**: 1183-1190 [PMID: 12538674]

72 **Malmassari SL**, Deng Q, Fontaine H, Houitte D, Rimlinger F, Thiers V, Maillere B, Pol S, Michel ML. Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope. *Hepatology* 2007; **45**: 1199-1209 [PMID: 17465004 DOI: 10.1002/hep.21594]

73 **Peng Z**, Zhang Y, Gu W, Wang Z, Li D, Zhang F, Qiu G, Xie K. Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules: a key to the cell cycle and apoptosis. *Int J Oncol* 2005; **26**: 467-473 [PMID: 15645132]

74 **Hwang GY**, Lin CY, Huang LM, Wang YH, Wang JC, Hsu CT, Yang SS, Wu CC. Detection of the hepatitis B virus X protein (HBx) antigen and anti-HBx antibodies in cases of human hepatocellular carcinoma. *J Clin Microbiol* 2003; **41**: 5598-5603 [PMID: 14662947]

75 **Martín-Vílchez S**, Sanz-Cameno P, Rodríguez-Muñoz Y, Majano PL, Molina-Jiménez F, López-Cabrera M, Moreno-Otero R, Lara-Pezzi E. The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. *Hepatology* 2008; **47**: 1872-1883 [PMID: 18449922 DOI: 10.1002/hep.22265]

76 **Tralhao JG**, Roudier J, Morosan S, Giannini C, Tu H, Goulenok C, Carnot F, Zavala F, Joulin V, Kremsdorf D, Bréchot C. Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: an alternative mechanism of HBx-related pathogenesis. *Proc Natl Acad Sci U S A* 2002; **99**: 6991-6996 [PMID: 12011457 DOI: 10.1073/pnas.092657699]

77 **Forgues M**, Difilippantonio MJ, Linke SP, Ried T, Nagashima K, Feden J, Valerie K, Fukasawa K, Wang XW. Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. *Mol Cell Biol* 2003; **23**: 5282-5292 [PMID: 12861014]

78 **Wen Y**, Golubkov VS, Strongin AY, Jiang W, Reed JC. Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. *J Biol Chem* 2008; **283**: 2793-2803 [PMID: 18032378]

79 **Martin-Lluesma S**, Schaeffer C, Robert EI, van Breugel PC, Leupin O, Hantz O, Strubin M. Hepatitis B virus X protein affects S phase progression leading to chromosome segregation defects by binding to damaged DNA binding protein 1. *Hepatology* 2008; **48**: 1467-1476 [PMID: 18781669 DOI: 10.1002/hep.22542]

80 **Kim S**, Park SY, Yong H, Famulski JK, Chae S, Lee JH, Kang CM, Saya H, Chan GK, Cho H. HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint. *Oncogene* 2008; **27**: 3457-3464 [PMID: 18193091]

81 **Yu FL**, Liu HJ, Lee JW, Liao MH, Shih WL. Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. *J Hepatol* 2005; **42**: 520-527 [PMID: 15763339]

82 **Ou DP**, Tao YM, Tang FQ, Yang LY. The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. *Int J Cancer* 2007; **120**: 1208-1214 [PMID: 17187364 DOI: 10.1002/ijc.22452]

83 **Chung TW**, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. *FASEB J* 2004; **18**: 1123-1125 [PMID: 15132991 DOI: 10.1096/fj.03-1429fje]

84 **Nguyen DH**, Ludgate L, Hu J. Hepatitis B virus-cell interactions and pathogenesis. *J Cell Physiol* 2008; **216**: 289-294 [PMID: 18302164 DOI: 10.1002/jcp.21416]

85 **Zhang X**, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. *J Lab Clin Med* 2006; **147**: 58-66 [PMID: 16459163]

86 **Cougot D**, Wu Y, Cairo S, Caramel J, Renard CA, Lévy L, Buendia MA, Neuveut C. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription. *J Biol Chem* 2007; **282**: 4277-4287 [PMID: 17158882]

87 **Barnabas S**, Hai T, Andrisani OM. The hepatitis B virus X protein enhances the DNA binding potential and transcription efficacy of bZip transcription factors. *J Biol Chem* 1997; **272**: 20684-20690 [PMID: 9252388]

88 **Abramovitch R**, Tavor E, Jacob-Hirsch J, Zeira E, Amariglio N, Pappo O, Rechavi G, Galun E, Honigman A. A pivotal role of cyclic AMP-responsive element binding protein in tumor progression. *Cancer Res* 2004; **64**: 1338-1346 [PMID: 14973073]

89 **Knoll S**, Fürst K, Thomas S, Villanueva Baselga S, Stoll A, Schaefer S, Pützer BM. Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC. *Cell Cycle* 2011; **10**: 3554-3565 [PMID: 22030623]

90 **Bergametti F**, Prigent S, Luber B, Benoit A, Tiollais P, Sarasin A, Transy C. The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines. *Oncogene* 1999; **18**: 2860-2871 [PMID: 10362257 DOI: 10.1038/sj.onc.1202643]

91 **Ahn JY**, Jung EY, Kwun HJ, Lee CW, Sung YC, Jang KL. Dual effects of hepatitis B virus X protein on the regulation of cell-cycle control depending on the status of cellular p53. *J Gen Virol* 2002; **83**: 2765-2772 [PMID: 12388812]

92 **Mathonnet G**, Lachance S, Alaoui-Jamali M, Drobetsky EA. Expression of hepatitis B virus X oncoprotein inhibits transcription-coupled nucleotide excision repair in human cells. *Mutat Res* 2004; **554**: 305-318 [PMID: 15450428 DOI: 10.1016/j.mrfmmm.2004.05.010]

93 **Lee AT**, Ren J, Wong ET, Ban KH, Lee LA, Lee CG. The hepatitis B virus X protein sensitizes HepG2 cells to UV light-induced DNA damage. *J Biol Chem* 2005; **280**: 33525-33535 [PMID: 16055925]

94 **Zhang SM**, Sun DC, Lou S, Bo XC, Lu Z, Qian XH, Wang SQ. HBx protein of hepatitis B virus (HBV) can form complex with mitochondrial HSP60 and HSP70. *Arch Virol* 2005; **150**: 1579-1590 [PMID: 15789261 DOI: 10.1007/s00705-005-0521-1]

95 **Yoo YG**, Na TY, Seo HW, Seong JK, Park CK, Shin YK, Lee MO. Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells. *Oncogene* 2008; **27**: 3405-3413 [PMID: 18264140]

96 **Han HK**, Han CY, Cheon EP, Lee J, Kang KW. Role of hypoxia-inducible factor-alpha in hepatitis-B-virus X protein-mediated MDR1 activation. *Biochem Biophys Res Commun* 2007; **357**: 567-573 [PMID: 17433259]

97 **Sanz-Cameno P**, Martín-Vílchez S, Lara-Pezzi E, Borque MJ, Salmerón J, Muñoz de Rueda P, Solís JA, López-Cabrera M, Moreno-Otero R. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. *Am J Pathol* 2006; **169**: 1215-1222 [PMID: 17003480]

98 **Arzumanyan A**, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. *Nat Rev Cancer* 2013; **13**: 123-135 [PMID: 23344543]

99 **Ding Q**, Xia W, Liu JC, Yang JY, Lee DF, Xia J, Bartholomeusz G, Li Y, Pan Y, Li Z, Bargou RC, Qin J, Lai CC, Tsai FJ, Tsai CH, Hung MC. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. *Mol Cell* 2005; **19**: 159-170 [PMID: 16039586]

100 **Lee JO**, Kwun HJ, Jung JK, Choi KH, Min DS, Jang KL. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. *Oncogene* 2005; **24**: 6617-6625 [PMID: 16007161]

101 **Wang LH**, Huang W, Lai MD, Su IJ. Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. *Carcinogenesis* 2012; **33**: 466-472 [PMID: 22159224]

102 **Xiao CX**, Yang XN, Huang QW, Zhang YQ, Lin BY, Liu JJ, Liu YP, Jazag A, Guleng B, Ren JL. ECHS1 acts as a novel HBsAg-binding protein enhancing apoptosis through the mitochondrial pathway in HepG2 cells. *Cancer Lett* 2013; **330**: 67-73 [PMID: 23178449]

103 **Liu YP**, Yang XN, Jazag A, Pan JS, Hu TH, Liu JJ, Guleng B, Ren JL. HBsAg inhibits the translocation of JTB into mitochondria in HepG2 cells and potentially plays a role in HCC progression. *PLoS One* 2012; **7**: e36914 [PMID: 22615844 DOI: 10.1371/journal.pone.0036914]

104 **Hsieh YH**, Su IJ, Yen CJ, Tsai TF, Tsai HW, Tsai HN, Huang YJ, Chen YY, Ai YL, Kao LY, Hsieh WC, Wu HC, Huang W. Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients. *Carcinogenesis* 2013; **34**: 475-485 [PMID: 23172669]

105 **Luan F**, Liu H, Gao L, Liu J, Sun Z, Ju Y, Hou N, Guo C, Liang X, Zhang L, Sun W, Ma C. Hepatitis B virus protein preS2 potentially promotes HCC development via its transcriptional activation of hTERT. *Gut* 2009; **58**: 1528-1537 [PMID: 19651630]

106 **Ferber MJ**, Montoya DP, Yu C, Aderca I, McGee A, Thorland EC, Nagorney DM, Gostout BS, Burgart LJ, Boix L, Bruix J, McMahon BJ, Cheung TH, Chung TK, Wong YF, Smith DI, Roberts LR. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. *Oncogene* 2003; **22**: 3813-3820 [PMID: 12802289 DOI: 10.1038/sj.onc.1206528]

107 **Liu H**, Shi W, Luan F, Xu S, Yang F, Sun W, Liu J, Ma C. Hepatitis B virus X protein upregulates transcriptional activation of human telomerase reverse transcriptase. *Virus Genes* 2010; **40**: 174-182 [PMID: 20107884 DOI: 10.1007/s11262-009-0441-3]

108 **Ozturk M**, Arslan-Ergul A, Bagislar S, Senturk S, Yuzugullu H. Senescence and immortality in hepatocellular carcinoma. *Cancer Lett* 2009; **286**: 103-113 [PMID: 19070423]

109 **Guerrieri F**, Belloni L, Pediconi N, Levrero M. Molecular mechanisms of HBV-associated hepatocarcinogenesis. *Semin Liver Dis* 2013; **33**: 147-156 [PMID: 23749671 DOI: 10.1055/s-0033-1345721]

110 **Zhang ZZ**, Liu X, Wang DQ, Teng MK, Niu LW, Huang AL, Liang Z. Hepatitis B virus and hepatocellular carcinoma at the miRNA level. *World J Gastroenterol* 2011; **17**: 3353-3358 [PMID: 21876625 DOI: 10.3748/wjg.v17.i28.3353]

111 **Lan SH**, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Lin YJ, Wu CT, Liu HS. Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. *Hepatology* 2014; **59**: 505-517 [PMID: 23913306 DOI: 10.1002/hep.26659]

112 **Song K**, Han C, Zhang J, Lu D, Dash S, Feitelson M, Lim K, Wu T. Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. *Hepatology* 2013; **58**: 1681-1692 [PMID: 23703729 DOI: 10.1002/hep.26514]

113 **Wang Y**, Jiang L, Ji X, Yang B, Zhang Y, Fu XD. Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor microRNA miR-15a/miR-16-1 in hepatocytes. *J Biol Chem* 2013; **288**: 18484-18493 [PMID: 23649629]

114 **Wei X**, Tan C, Tang C, Ren G, Xiang T, Qiu Z, Liu R, Wu Z. Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. *Cell Signal* 2013; **25**: 1037-1043 [PMID: 23376496]

115 **Xu X**, Fan Z, Kang L, Han J, Jiang C, Zheng X, Zhu Z, Jiao H, Lin J, Jiang K, Ding L, Zhang H, Cheng L, Fu H, Song Y, Jiang Y, Liu J, Wang R, Du N, Ye Q. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. *J Clin Invest* 2013; **123**: 630-645 [PMID: 23321675]

116 **Xu C**, Zhou W, Wang Y, Qiao L. Hepatitis B virus-induced hepatocellular carcinoma. *Cancer Lett* 2014; **345**: 216-222 [PMID: 23981576]

117 **Ayub A**, Ashfaq UA, Haque A. HBV induced HCC: major risk factors from genetic to molecular level. *Biomed Res Int* 2013; **2013**: 810461 [PMID: 23991421 DOI: 10.1155/2013/810461]

118 **Bharadwaj M**, Roy G, Dutta K, Misbah M, Husain M, Hussain S. Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. *Cancer Metastasis Rev* 2013; **32**: 229-268 [PMID: 23114844 DOI: 10.1007/s10555-012-9412-6]

119 **Galuppo R,** Ramaiah D, Ponte OM, Gedaly R. Molecular Therapies in Hepatocellular Carcinoma: What Can We Target? *Dig Dis Sci* 2014; [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x]

120 **Shin JW**, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: current and future. *World J Gastroenterol* 2013; **19**: 6144-6155 [PMID: 24115810 DOI: 10.3748/wjg.v19.i37.6144]

**P-Reviewers:** Guo Y **S-Editor:** Qi Y **L-Editor: E-Editor:**